NLS antaros medical

Emeriti Pharma, which is developing a new treatment for skin diseases, takes up two million in venture capital from Antaros Medical. The existing owner, Almi Invest, is also participating in the funding, which has a total value of three million SEK. Emeriti Pharma also announces that the company is currently conducting a Phase 1 study […]

Antaros Medical, Sahlgrenska University Hospital and AstraZeneca have announced a kidney imaging collaboration aiming to develop new tools to treat chronic kidney disease (CKD). The collaboration partners will work together on a study to examine a range of imaging endpoints in patients with CKD. The aim is to determine which imaging biomarkers are best suited to follow CKD progression […]

Antaros Medical has  appointed Carl Sjöberg as the Director R&D Imaging. Carl Sjöberg, MSc, is a widely experienced software developer with background within physics engineering and medical physics, and is now joining Antaros Medical CoreLab in Uppsala. In this strategically important role, Carl will further strengthen Antaros unique portfolio of innovative MRI/PET techniques and also further develop […]

Antaros Medical, a service provider in drug development using imaging, has made two key appointments, Klas Malmberg, as the Chief Medical Officer and Elisabeth Bolling-Sternevald, as the Chief Operating Officer. Klas Malmberg MD, PhD, FESC, is an experienced cardiologist, medical expert and senior lecturer with wide experience from both academic and pharmaceutical industry. Klas extensive merit list […]

Antaros Medical, has entered into a research agreement with  SANOFI. The project seeks to increase the understanding of the activity of certain incretins and underscores the vital role Antaros Medical plays as a trusted partner to major drug manufacturers. “The Antaros team has an impressive track record in early clinical experimentation and clinical functional imaging. […]